• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Tengion

edit

Tengion, a clinical-stage biotechnology company, is a leader in developing neo-organs and neo-tissues, currently derived from a patient’s own (autologous) cells. The Company has completed two Phase 2 human clinical trial in the United States with its Tengion Neo-Bladder Augmentâ„¢ for children with neurogenic bladder due to spina bifida and in adults with neurogenic bladder due to spinal cord injury. A successful academic human clinical experience with a urinary Neo-Bladder Augment was reported in The Lancet in April 2006 by investigators from the Children’s Hospital Boston. Tengion has an effective investigational new drug application (IND) for its Neo-Urinary Conduitâ„¢ and expects to begin a Phase 1 clinical trial in the first half of 2010 in bladder cancer patients requiring bladder removal.

Milestones

edit

• 
  Went public with stock symbol NASDAQ:TNGN. (4/9/10)
  Posted 7/2/10 at 12:23pm
• 
  Tengion received $39M in Series A funding. (8/3/05)
  Posted 7/1/10 at 4:23am via corporate-ir.net
• 
  Tengion received $50M in Series B funding. (6/23/06)
  Posted 4/19/10 at 9:52pm via tengion.com
• 
  Tengion received $33M in Series C funding. (10/15/07)
  Posted 3/10/10 at 10:51pm via tengion.com

Videos

Screenshots

edit

Above: Tengion
Uploaded: 3/11/10

Stock Price

Sources

1. Tengion Inc. Completes $39 Million Series "A" Round Financing Will Advance Development of Regenerative Medicine Products (phx.corporate-ir.net) [edit]
2. Tengion Inc. Completes $50 Million Series "B" Round Financing led by Bain Capital and Quaker BioVentures will support neo-bladder clinical trials, manufacturing capacity and pipeline development (tengion.com) [edit]
3. Tengion Closes $33 Million in Series C Funding Deerfield Partners Joins Investor Group as Company Advances Novel Regenerative Medicine Products (tengion.com) [edit]